gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.


Glucagon, Glucagon-Like Peptide 1, GLP-1
The protein encoded by this gene is actually a preproprotein that is cleaved into four distinct mature peptides. One of these, glucagon, is a pancreatic hormone that counteracts the glucose-lowering action of insulin by stimulating glycogenolysis and gluconeogenesis. Glucagon is a ligand for a specific G-protein linked receptor whose signalling pathway controls cell proliferation. Two of the other peptides are secreted from gut endocrine cells and promote nutrient absorption through distinct mechanisms. Finally, the fourth peptide is similar to glicentin, an active enteroglucagon. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: E4, Insulin, HAD, CAN, V1a
Papers on Glucagon
Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.
Knowles et al., Stanford, United States. In Curr Atheroscler Rep, Feb 2016
Glucagon-like peptide-1 (GLP-1) is a key hormone in the pathophysiology of diabetes.
Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of lixisenatide and other glucagon-like peptide-1 receptor agonists.
Pozzilli et al., Bari, Italy. In Diabetes Metab Res Rev, Feb 2016
In this review, the options for treatment intensification will be explored, focusing on drug classes that act via the incretin system and paying particular attention to the short-acting glucagon-like peptide-1 receptor agonist lixisenatide.
Intestinal Bile Acid Composition Modulates Prohormone Convertase 1/3 (PC1/3) Expression and Consequent GLP-1 Production in male mice.
Itoh et al., Tokyo, Japan. In Endocrinology, Feb 2016
Although the mechanisms underlying these effects are still enigmatic, GLP-1 appears to be involved.
Puerarin protects pancreatic β-cells in obese diabetic mice via activation of GLP-1R signaling.
Shu et al., Nanjing, China. In Mol Endocrinol, Feb 2016
Glucagon-like peptide 1 receptor (GLP-1R) signaling plays an important role in β-cell survival and function.
Comparative Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Glucose Homeostasis and Incretin Hormones in Obese Type 2 Diabetic Patients: A One-Year Prospective Study.
Capaldo et al., Napoli, Italy. In Horm Metab Res, Feb 2016
Meal-stimulated GLP-1 levels increased after both procedures reaching significantly higher levels after RYGB (p=0.0001).
Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery.
Madsbad et al., Copenhagen, Denmark. In Am J Physiol Endocrinol Metab, Feb 2016
UNASSIGNED: Exaggerated secretion of glucagon-like peptide 1 (GLP-1) is important for postprandial glucose tolerance after Roux-en-Y gastric bypass (RYGB), whereas the role of glucose-dependent insulinotropic polypeptide (GIP) remains to be resolved.
GLP-1 based therapies: clinical implications for gastroenterologists.
Cahen et al., Amsterdam, Netherlands. In Gut, Feb 2016
UNASSIGNED: The gut-derived incretin hormone, glucagon-like peptide 1 (GLP-1) lowers postprandial blood glucose levels by stimulating insulin and inhibiting glucagon secretion.
Long-term effects of duodenojejunal bypass on diabetes in Otsuka Long-Evans Tokushima Fatty rats.
Kim et al., Taejŏn, South Korea. In Asian J Surg, Feb 2016
Thereafter, we measured daily body weight, serum levels of glucose and gut hormones such as glucagon-like peptide-1, insulin, and leptin.
IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes.
Hughes, Ryde, United Kingdom. In Prim Care Diabetes, Feb 2016
With complementary modes of action, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and a basal insulin in combination offer an alternative to basal-bolus therapy in T2D.
TCF1 links GIPR signaling to the control of beta cell function and survival.
Drucker et al., Toronto, Canada. In Nat Med, Jan 2016
The glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor transduce nutrient-stimulated signals to control beta cell function.
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
ELIXA Investigators et al., Glasgow, United Kingdom. In N Engl J Med, Jan 2016
We assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascular outcomes in patients with type 2 diabetes who had had a recent acute coronary event.
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Newsome et al., Birmingham, United Kingdom. In Lancet, Dec 2015
BACKGROUND: Glucagon-like peptide-1 (GLP-1) analogues reduce hepatic steatosis, concentrations of liver enzymes, and insulin resistance in murine models of fatty liver disease.
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
SCALE Obesity and Prediabetes NN8022-1839 Study Group et al., Frederiksberg, Denmark. In N Engl J Med, Aug 2015
Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously.
Can encapsulated glutamine increase GLP-1 secretion, improve glucose tolerance, and reduce meal size in healthy volunteers? A randomised, placebo-controlled, cross-over trial.
Gribble et al., Cambridge, United Kingdom. In Lancet, Mar 2015
Weight loss after surgery has been attributed to increased nutrient delivery to the lower small intestine with release of satiety-promoting gut hormones such as glucagon-like peptide 1 (GLP-1).
Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors.
Jang et al., Seoul, South Korea. In Evid Based Complement Alternat Med, 2014
Glucagon-like peptide-1 (GLP-1) participates in glucose homeostasis and feeding behavior.
Exogenous and endogenous ghrelin counteracts GLP-1 action to stimulate cAMP signaling and insulin secretion in islet β-cells.
Yada et al., Tochigi, Japan. In Febs Lett, 2012
Exogenous and endogenous ghrelin counteracts GLP-1 action to stimulate cAMP signaling and insulin secretion in islet beta-cells
Elevated glucagon-like peptide-1 plasma levels, as a possible adaptive response, in diabetic NOD mice.
Sandler et al., Uppsala, Sweden. In Biochem Biophys Res Commun, 2012
this study is the first to show increased levels of GLP-1 in plasma in spontaneously diabetic NOD mice.
Biophysical and pharmacological properties of glucagon-like peptide-1 in rats under isoflurane anesthesia.
Yokoyama et al., Kōchi, Japan. In Anesth Analg, 2012
GLP-1 secretion is impaired during isoflurane anesthesia, but the insulinotropic action of GLP-1 was not affected by isoflurane.
Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine.
Poulsen et al., Copenhagen, Denmark. In Cancer Chemother Pharmacol, 2012
The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors.
Skibicka et al., Göteborg, Sweden. In J Neurosci, 2012
A novel neurobiological mechanism is demonstrated for GLP-1-induced anorexia in rats, involving direct effects of a GLP-1 analogue, Exendin-4 (EX4) on food reward that are exerted at the level of the mesolimbic reward system.
share on facebooktweetadd +1mail to friends